WORLDWIDE AGREEMENT ON THE PRINCIPLES OF ARCELOR’S CORPORATE SOCIAL RESPONSIBILITYWorldwide Agreement • September 29th, 2005 • Luxembourg
ARCELOR has committed itself on a worldwide basis to a sustainable development strategy, whose aim is to make its economic, environmental and social objectives coherent. In this context, ARCELOR now intends to resume and bring together all the priorities of its global social policy in this agreement, in order to develop and formalise its principles of responsibility.
Worldwide Agreement:Worldwide Agreement • October 21st, 2013
CAD/CAM for CNC machining industries, has extended two of its most popular software packages to include useful web-based tools that enhance the way sign and print providers do business. SAi Flexi Cloud and SAi PhotoPRINT Cloud install locally to the user’s computer, but deliver added value through the Cloud, thereby bringing Internet-based capability and added-value functionality to SAi’s best-known brands.
Worldwide Agreement: Safe Biotech Foods On Our PlatesWorldwide Agreement • August 20th, 2021
Crops improved through biotechnology have been adopted by farmers in the United States and around the world at rates never before seen by any other advances in the history of agriculture. Much of those crops have been fed to livestock and poultry. There has not been one single documented health problem associated with consumption of meat, milk and eggs from livestock and poultry fed biotech crops. From the first significant commercial plantings in 1996, double digit growth in each subsequent year has led to more than 252 million acres of biotech crops planted in 2006 in 22 countries. These crops are grown by 10.5 million farmers — 9.5 million of whom are small-scale farmers in the developing world. The reason for such impressive adoption rates is simple — agricultural biotechnology delivers significant and tangible benefits, all the way from farm to fork.
CONFIDENTIAL PROVISIONS REDACTED SECOND AMENDED AND RESTATED WORLDWIDE AGREEMENTWorldwide Agreement • March 16th, 2006 • PDL Biopharma, Inc. • Biological products, (no disgnostic substances)
This Second Amended and Restated Worldwide Agreement is entered into as of October 28, 2005 (the “Amendment Effective Date”), by and among, on the one hand, HOFFMANN-LA ROCHE INC., a New Jersey corporation having offices at 340 Kingsland Street, Nutley, New Jersey 07110 (“Roche-Nutley”) and F. HOFFMANN-LA ROCHE LTD of Basel, Switzerland (“F. Roche”) (Roche-Nutley and F. Roche are hereinafter individually and collectively referred to as “Roche”) and, on the other hand, PROTEIN DESIGN LABS, INC., a Delaware corporation having offices at 34801 Campus Drive, Fremont, California 94555 (“PDL”).
